TNDM241018C42500
- 2.62
- -1.18-31.05%
Tandem Diabetes Care Newsroom
Tandem Diabetes Care Is Maintained at Equal-Weight by Morgan Stanley
Tandem Diabetes Care Analyst Ratings
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF) and Tandem Diabetes Care (TNDM)
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Morgan Stanley Initiates Tandem Diabetes Care(TNDM.US) With Hold Rating, Announces Target Price $45
Tandem Diabetes Care Analyst Ratings
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75
Lake Street Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)
CCORF Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $57
Critical Insights From Tandem Diabetes Care Analyst Ratings: What You Need To Know
Analysts' Top Healthcare Picks: Xtant Medical Holdings (XTNT), Tandem Diabetes Care (TNDM)
Canaccord Genuity Initiates Coverage on Tandem Diabetes Care With Buy Rating, $57 Price Target
Tandem Diabetes Care Price Target Announced at $57.00/Share by Canaccord Genuity
Tandem Diabetes Care Analyst Ratings
Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $58
Analysts Conflicted on These Healthcare Names: Owens & Minor (OMI), Tandem Diabetes Care (TNDM) and Alignment Healthcare (ALHC)
Baird Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $39